Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C
2011 StandoutNobel
Plant Cuticular Lipid Export Requires an ABC Transporter
2004 StandoutScience
Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats
2004
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
2001 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Gastric cancer
2016 Standout
Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum
2005
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
2002
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma
2002
EGFR Antagonists in Cancer Treatment
2008 Standout
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
2007
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Capecitabine
2001
Polymeric drug delivery of platinum-based anticancer agents
2008
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
2016
Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6*
1998
Ovarian cancer
2014 Standout
The Product of the ABC Half-Transporter Gene ABCG2 (BCRP/MXR/ABCP) Is Expressed in the Plasma Membrane
2000
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
2010
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines
2001
Drug development and clinical trials—the path to an approved cancer drug
2012
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Self-Renewal, Multipotency, and the Existence of Two Cell Populations within an Epithelial Stem Cell Niche
2004 Standout
Drug-Induced Hepatotoxicity
2003 Standout
Nasopharyngeal carcinoma
2019 Standout
The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, Capecitabine
2000
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
2001
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization
2001
The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
2008
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Capecitabine
2003
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
2009
Fluorescent method for platinum detection in buffers and serums for cancer medicine and occupational hazards
2008
Raise standards for preclinical cancer research
2012 StandoutNature
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
2002
A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer
2005
Capecitabine: A review
2005
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
2004
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
2001
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin
2002
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
2011
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area
2006
Functional Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect Cells
2001
Side population cells in human and mouse epidermis lack stem cell characteristics
2004
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
2009
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan
2007
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability
2016 StandoutNobel
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
2009
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
2000
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
2001
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
ToppGene Suite for gene list enrichment analysis and candidate gene prioritization
2009 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Cancer of the Ovary
2004 Standout
Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance
2014
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Luminescent Chemodosimeters for Bioimaging
2012 Standout
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
2009
Expression and functional analyses of breast cancer resistance protein in lung cancer.
2003
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Current states and future views in photodynamic therapy
2011
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
Breast Cancer Resistance Protein (BCRP) in Acute Leukaemia
2003
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination
2009 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
An Evolutionary View of the Mechanism for Immune and Genome Diversity
2012 StandoutNobel
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
2001
Mammalian ABC Transporters in Health and Disease
2002
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
2007
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
2000
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
2002
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
2001
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
2001
Topoisomerase I inhibitors: selectivity and cellular resistance
1999
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
2001
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
Evolutionary Comparison of the Mechanism of DNA Cleavage with Respect to Immune Diversity and Genomic Instability
2012 StandoutNobel
A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors
2004
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
2008
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.
2000
Dose translation from animal to human studies revisited
2007 Standout
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of J. Schellens being referenced
Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry
2007
Oral topotecan: bioavailability and effect of food co-administration
1999
Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry
2000
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
2002
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
1998
Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry
2002
Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a ‘cocktail’ approach
1989
Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications
2000
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
2000
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood
2003
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
2000
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
1999